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Abstract
Background: Dietary n-3-polyunsaturated fatty acids (n-3-PUFA) have been shown to reduce
body weight and fat mass in rodents as well as in humans in one small short-term study. We
conducted this controlled randomized dietary trial to test the hypothesis that n-3-PUFA lower
body weight and fat mass by reducing appetite and ad libitum food intake and/or by increasing
energy expenditure.
Methods: Twenty-six overweight or moderately obese (body mass index 28–33 kg/m2) men and
women were included, and received either a diet rich in n-3-PUFA from both plant and marine
sources or a control diet. Diets were administered in an isocaloric fashion for 2 weeks followed by
12 weeks of ad libitum intake. The n-3-PUFA and control diets were identical in all regards except
for the fatty acid composition. All foods were provided to subjects, and leftovers were weighed
back to assess actual food intake accurately for each day of the study. This design gave us 80%
power to detect a difference in weight change between the n-3-PUFA and control diet groups of
2.25 kg at an α-error level of 5%.
Results: Both groups lost similar amounts of weight when these diets were consumed ad libitum
for 12 weeks [mean (SD): -3.5 (3.7) kg in the control group vs. -2.8 (3.7) kg in the n-3-PUFA group,
F(1,24) = 13.425, p = 0.001 for time effect; F(1,24) = 0.385, p = 0.541 for time × group interaction].
Consistent with this finding, we also found no differences between the n-3-PUFA and control
groups with regard to appetite as measured by visual analogue scale, ad libitum food intake, resting
energy expenditure as measured by indirect calorimetry, diurnal plasma leptin concentrations, or
fasting ghrelin concentrations.
Conclusion: Our results suggest that dietary n-3-PUFA do not play an important role in the
regulation of food intake, energy expenditure, or body weight in humans.
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Introduction
Overweight and obesity are major public health concerns
[1], and effective long-term treatments for these condi-
tions are lacking [2]. Foods that reduce appetite or
increase satiety or energy expenditure might be helpful in
achieving and sustaining weight loss. Diets rich in n-3-
PUFA are associated with lower plasma leptin concentra-
tions than diets with a low n-3-PUFA content in healthy
humans [3-5]. The fact that reduced leptin concentrations
in these studies were not associated with increased hunger
or decreased energy expenditure suggested that dietary n-
3-PUFA might increase leptin sensitivity. Indeed, con-
sumption of diets rich in n-3-PUFA has repeatedly been
associated with reduced food intake, increased energy
expenditure, and/or lower body weight and fat mass – all
indicators of increased leptin 'action' – in rats [6,7], mice
[8,9], and one short-term study in humans [10]. Remark-
ably, a lower body weight or fat mass was observed in
studies that controlled calorie intake, such as in the study
of Baillie et al. who pair-fed the fish oil fed mice to mice
receiving a control diet low in n-3-PUFA [6], and in ad libi-
tum feeding studies [7,8,10]. As well-controlled longer-
term studies in humans were lacking, we conducted a ran-
domized controlled 16-week trial in healthy overweight
or moderately obese men and women to test the hypoth-
esis that a diet rich in n-3-PUFA from both plant and
marine sources would reduce body weight by decreasing
appetite and ad libitum food intake and/or by increasing
resting energy expenditure.
Experimental methods
Subjects
Subjects were 26 healthy overweight or mildly obese
(body mass index 28–33 kg/m2) men and women. Sub-
jects were weight stable [within 2.27 kg (5 pounds) in the
past 6 months] and within 4.54 kg (10 pounds) of their
lifetime maximum weight. Exclusion criteria included the
use of tobacco or recreational drugs, alcohol abuse, a his-
tory of cardiovascular disease or diabetes mellitus, the
presence of any chronic or psychiatric illness, restrictive
eating behavior, pregnancy, and the intake of selective
serotonin-reuptake inhibitors, lipid-lowering drugs, β-
blockers, glucocorticoids, or anabolic steroids. All subjects
underwent informed consent procedures. The study pro-
tocol was approved by the University of Washington Insti-
tutional Review Board (#03-9082-D05), and was in
compliance with the Helsinki Declaration.
Study design
In the first two weeks of the study, all subjects consumed
a control diet. Caloric content of the diet was calculated
on the basis of a 3-day diet record completed by the sub-
jects, and the Mifflin formula [11] adjusted for an activity
factor based on a modified Blair physical activity ques-
tionnaire [12] to maintain each subject's weight to within
1 kg of baseline weight. Subjects were instructed to con-
sume all food provided, not to eat any additional food,
and to take a portion of their calculated daily fat intake as
capsules filled with high-oleic safflower oil. They were
asked to keep a daily food record and write down all the
foods they had eaten, estimate the percentage eaten, and
any deviations from the diet protocol. On the morning of
day 14 of the control diet, subjects were admitted to the
University of Washington Clinical Research Center (CRC)
after an overnight fast of at least 10 hours for clinic visit
#1 (CRC 1).
Upon completion of CRC 1, subjects were randomized to
continue consuming the control diet or to consume a diet
enriched in n-3-PUFA, for another two weeks. The n-3-
PUFA diet was identical to the control diet in all respects
apart from the sources of dietary fat. A portion of the aug-
mented n-3-PUFA intake was provided by switching the
subjects from capsules containing high-oleic safflower oil
to an identical number of capsules containing fish oil,
with the balance of the n-3-PUFA provided in prepared
foods [13]. The n-3-PUFA diet contained 1.4% of energy
in the form of the long-chain n-3-PUFA eicosapentaenoic
acid (20:5n-3), docosapentaenoic acid (22:5n-3), and
docosahexaenoic acid (22:6n-3), and 2.2% of energy in
the form of α-linolenic acid (18:3n-3) from plant oils,
while the control diet provided 0% of energy in the form
of marine n-3-PUFA and 0.5% of energy as α-linolenic
acid. Subjects continued to pick up food, turn in food
records, and were weighed twice weekly. The total caloric
content of dispensed food items was identical to the
amount that led to weight stability in the lead-in diet
period ('isoenergetic'). The subjects were again instructed
to consume all food and not to eat any other food. On day
14 of this period, subjects were again admitted to the CRC
for visit 2.
After CRC 2, subjects continued to consume the diets to
which they had been randomized for another 12 weeks
but now freely chose the amount they wished to eat (ad
libitum). In this phase, the caloric content of food pro-
vided to subjects was 115% of the amount they had
received in the previous isoenergetic period. Subjects con-
tinued to weigh twice weekly, pick up food and return
uneaten food items, allowing an accurate assessment of
the calories consumed on each day of the study. During
each food pick-up visit, subjects met with a dietitian for
about 15 minutes to review the food records and the
returned, uneaten foods. This meeting and the compari-
son of the food records and returned foods were imple-
mented as they provided valuable information about the
compliance of the subject. Specifically, meeting with the
subject in person twice weekly for the 16-week dietary
period created a rapport with the subject and helped us
respond in a timely fashion to specific requests such asNutrition & Metabolism 2009, 6:24 http://www.nutritionandmetabolism.com/content/6/1/24
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switching specific meals or foods. Further, any major or
repeated deviations from the study protocol would have
required a substantial investment of time and effort from
the subject to make sure that the amounts of foods
returned were always consistent with those recorded on
the food diary. To further increase compliance, subjects
were allowed to drink up to 30 alcoholic drinks, and to
exchange up to 10 study meals for "meals out" or meals
prepared at home during the first 10 weeks of the ad libi-
tum diet period. We asked subjects to provide detailed
information about alcoholic beverages and meals out on
the daily food record. Specifically, we asked them to note
the amount and type of alcoholic beverage consumed,
and to provide recipes for meals prepared at home,
including details such as the amounts and sources of die-
tary fat. If they had a meal at a restaurant, we asked them
to provide the names of the restaurant and the dish they
had chosen. A dietitian of the CRC Nutrition Research
Kitchen would then call the restaurant to obtain more
detailed information about the dish. Of note, 18 out of
the 26 subjects who completed the study exchanged a
study meal for a "meal out" on less than the allowed 10
occasions, suggesting an excellent compliance with the
dietary regimen. On day 84 of this diet period, subjects
were again admitted to the CRC for visit 3.
During each of the three admissions to the CRC, subjects
were weighed immediately after the first morning voiding.
Breakfast, lunch, dinner and a snack were served at 0800,
1200, 1730, and 2000, respectively, and subjects were
asked to complete each meal within 30 minutes. An intra-
venous line was used to sample 5 ml of blood every half-
hour between 0800 and 2100, and every hour between
2100 and 0800 the next day. Additional fasting blood
samples were drawn at 0800 on day 2 of each CRC visit
and plasma prepared from all samples was kept frozen at
-70°C until analyses. The 38 diurnal plasma samples were
frozen individually, for measurement of plasma leptin
concentrations. During CRC visits 1 and 3, a whole-body
dual-energy x-ray absorptiometry scan was performed
using a GE Lunar Prodigy (General Electric Healthcare,
Waukesha, Wisconsin, USA) scanner to assess body fat
mass. At 0700 on day 2 of each CRC admission, we per-
formed indirect calorimetry for 30 minutes to assess rest-
ing energy expenditure using a TrueOne 2400 metabolic
cart (Parvo Medics, Sandy, Utah, USA). Throughout the
study, subjects completed daily visual analogue scale
(VAS) questionnaires to assess hunger and fullness. They
were also asked to complete a modified Blair physical
activity questionnaire [12] every 2–4 weeks. Additional
details about subject characteristics and study design have
been published previously [13].
Laboratory methods
Plasma leptin and ghrelin were measured in duplicate by
commercially available radioimmunoassays (Millipore,
Billerica, Massachusetts, USA). Leptin was measured in all
38 timed diurnal samples drawn during each of the three
clinic visits. Ghrelin was measured in fasting samples, and
in pools of plasma created from the timed blood samples
by combining 50 μL plasma from each blood sample
drawn at 30-minute intervals and 100 μL plasma from
each blood sample drawn at 60-minute intervals ('pool'-
sample). Intra- and interassay CV were 2.4% and 3.6%,
respectively, for leptin, and 4.3% and 5.3%, respectively,
for ghrelin.
Statistical analyses
Sample size calculation revealed that completing 36 sub-
jects would provide 80% power to find a difference in
body weight of 2.25 kg between the n-3-PUFA and control
groups. The estimate for the variability in body weight
change over the 12-week ad libitum diet period was
derived from two previous controlled dietary trials con-
ducted by our group that had employed an identical
design [14,15]. We determined that we wanted to perform
one interim analysis after 26 subjects had completed the
study, which would allow us either to stop the study for
effect or futility or to continue until the full 36 subjects
had completed the study. We therefore designed this
study as a sequential clinical trial, using the Power Family
of Two-Sided, Inner Wedge Tests (chapter 5 in [16]). This
test was chosen as it ensures specified α-error and power
conditions [16].
Analyses were performed using SPSS, version 11.5 (SPSS
Inc., Chicago, Illinois, USA). Changes in body weight,
body fat mass, fasting leptin, the area under the leptin
curve, and the leptin peak-nadir were compared by
repeated measures analysis of variance (RM-ANOVA),
with the three time points (CRC 1, CRC 2, and CRC 3) as
the three levels of the within-subjects factor (time), and
treatment (control vs. n-3-PUFA) as the between-subjects
factor. Post hoc, we performed another RM-ANOVA, with
a reduced number of the within-subjects factor by includ-
ing either just CRC 1 and 2, or CRC 2 and 3. If the assump-
tion of sphericity did not hold, degrees of freedom were
adjusted according to Greenhouse & Geisser. Friedman
tests separately for each group were performed if the resid-
uals were not normally distributed, which was the case
only for physical activity. The level of significance was set
to p < 0.05.
Results
The one interim analysis that was performed according to
the statistical protocol after 26 subjects had completed the
study showed that both groups lost similar amounts of
weight during the ad libitum phase [-3.5 (3.7) kg controlNutrition & Metabolism 2009, 6:24 http://www.nutritionandmetabolism.com/content/6/1/24
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vs. -2.8 (3.7) kg n-3-PUFA, mean (SD), Figure 1], which
was significant overall [time effect in RM-ANOVA, F(1,24) =
13.425, p = 0.001], but not different between the two
groups [time × group interaction, F(1,24) = 0.385, p =
0.541] [13]. We therefore stopped the study for futility, as
determined in the formal stopping rules. Similarly,
changes in body composition and particularly fat mass
were similar between the two groups, as reported earlier
[13].
The area-under-the diurnal plasma leptin curve did not
change between CRC 1 and CRC 2 in either group [time:
F(1,24) = 1.927, p = 0.178; time × group: F(1,24) = 0.594, p =
0.449 in RM-ANOVA], but decreased when subjects lost
weight during the ad libitum period by 450 ± 896 arbitrary
units (AU) in the control group, and by 350 ± 705 AU in
the n-3-PUFA group [time: F(1,24) = 6.394, p = 0.018, time
× group: F(1,24) = 0.100, p = 0.754 in RM-ANOVA; Figure
2]. Fasting ghrelin concentrations in plasma increased
moderately by ~7% in both groups when subjects lost
weight during the ad libitum period, but were not different
between the groups (Table 1). Changes in ghrelin concen-
trations in the 'pool'-sample reflecting the average ghrelin
concentrations throughout each of the 24-hour clinic vis-
its were similar to those observed in fasting plasma (Table
1).
No changes were observed in hunger and fullness ratings
as assessed by VAS throughout the study (data not
shown). Compared to the isoenergetic periods, food
intake tended to be lower in the ad libitum period in both
groups [-0.74 ± 1.47 MJ/d control vs. -0.39 ± 1.61 MJ/d n-
3-PUFA, time effect in RM-ANOVA: F(1.100,26.409) = 2.994,
p = 0.092], but without any difference between the groups
[time × group interaction: F(1.100,26.409) = 0.395, p = 0.555;
Table 2]. Similarly, resting energy expenditure as the
major component of daily energy expenditure did not
change throughout the study, and was not different
between the two groups [time: F(2,46) = 0.313, p = 0.733;
time × group: F(2,46) = 0.703, p = 0.500 in RM-ANOVA].
Lastly, physical activity remained constant in both groups
throughout the study [χ2
(5) = 6.156, p = 0.291 for control
and χ2
(5) = 7.313, p = 0.198 for n-3-PUFA group, Fried-
man tests; Table 2].
Discussion
Our well-controlled 16-week study showed that increas-
ing dietary n-3-PUFA content to 3.6% of total energy did
not have an effect on plasma leptin levels, body weight or
fat mass in overweight or moderately obese, healthy men
and women. We designed the study as a sequential clinical
trial, using the power family of two-sided, inner wedge
tests (chapter 5 in [16]). This test was chosen as it ensures
specified α-error and power conditions [16], indicating
we had sufficient power to confidently accept the null
hypothesis of no difference between the two groups at this
point.
We decided not to administer more than 3.6% of energy
in the form of n-3-PUFA, as higher intakes are not realistic
over an extended period of time in a free-living popula-
tion. Endpoints affected by leptin signaling such as resting
energy expenditure, appetite, or ad libitum food intake
were not different between the n-3-PUFA and control
diets, suggesting that n-3-PUFA do not increase leptin sen-
sitivity as hypothesized. Our findings are consistent with
those of Krebs and colleagues [17] who studied cardiovas-
cular endpoints in 93 overweight women randomized to
a weight loss diet with or without n-3-PUFA (fish oil), or
to a control diet. Weight loss over 12 and 24 weeks was
independent of the n-3-PUFA content of the diets.
These results are in contrast, however, to several studies in
rodents [6-9], and one small short-term study in humans
[10]. Couet et al. fed normal weight subjects control diets
for 3 weeks, followed by diets rich in n-3-PUFA for
another 3 weeks [10]. While weight loss in these two peri-
ods was similar, the subjects lost more fat mass when they
consumed the n-3-PUFA-rich diet (-0.88 ± 0.16 vs. -0.30 ±
0.34 kg, p = 0.02). Based on our results and those of Krebs
and colleagues, it seems possible that the findings by
Couet et al. were due to chance based on their small sam-
Change in body weight in both groups, in relation to the  average daily intake of n-3-polyunsaturated fatty acids Figure 1
Change in body weight in both groups, in relation to 
the average daily intake of n-3-polyunsaturated fatty 
acids.
-15
-10
-5
0
5
0 0.5 1 1.5 2 2.5 3 3.5 4
C
h
a
n
g
e
 
i
n
 
b
o
d
y
 
w
e
i
g
h
t
 
t
h
r
o
u
g
h
o
u
t
 
t
h
e
 
s
t
u
d
y
 
(
k
g
)
N-3-polyunsaturated fatty acid intake (% of energy)Nutrition & Metabolism 2009, 6:24 http://www.nutritionandmetabolism.com/content/6/1/24
Page 5 of 7
(page number not for citation purposes)
Diurnal plasma leptin concentrations during clinical research center (CRC) visits 1, 2, and 3 in subjects consuming the control  diet (a, n = 13) or the diet rich in n-3-polyunsaturated fatty acids (b, n = 13) Figure 2
Diurnal plasma leptin concentrations during clinical research center (CRC) visits 1, 2, and 3 in subjects con-
suming the control diet (a, n = 13) or the diet rich in n-3-polyunsaturated fatty acids (b, n = 13). Blood was drawn 
every 30' between 0800 and 2100, and every 60' thereafter. Meals were consumed at 0800, 1200, 1730, and 2000 immediately 
after the respective blood draws, and subjects were requested to complete the meal within 30'. Data are expressed in % of the 
CRC 1 0800 value, and represent means and standard errors of the means.
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Table 1: Plasma ghrelin concentrations throughout the study
RM-ANOVA *
CRC 1 † CRC 2 CRC 3 Time Time × Group
Fasting plasma ghrelin (pg/mL):
Control group (n = 13) 766 (118) 780 (127) 820 (139) F(2,48) = 4.058; F(2,48) = 0.071;
n-3-PUFA group (n = 13) 687 (189) 708 (244) 734 (241) p = 0.024 p = 0.931
Plasma ghrelin in 'pool'-sample (pg/mL)
Control group (n = 13) 760 (148) 770 (116) 800 (159) F(2,48) = 4,799; F(2,48) = 0.300;
n-3-PUFA group (n = 13) 687 (211) 706 (249) 718 (235) p = 0.013 p = 0.742
All data are means (SD). * RM-ANOVA, repeated measures analysis of variance. † CRC, Clinical Research Center.
Table 2: Calorie intake, physical activity, and resting energy expenditure throughout the study
Lead-in period (2 weeks) Isoenergetic period 
(2 weeks)
Ad libitum period 
(12 weeks)
Friedman tests
Physical activity (MET-h/d)*:
Control group (n = 13) 38.2 (19.9) 38.6 (22.7) 37.4 (21.7) χ2
(5) = 6.156, p = 0.291
n-3-PUFA3 group 
(n = 13)
54.8 (29.9) 62.0 (29.9) 57.5 (29.6) χ2
(5) = 7.313, p = 0.198
RM-ANOVA†
Time Time × Group
Calorie intake (MJ/d):
Control group (n = 13) 10.9 (1.5) 10.9 (1.3) 10.2 (1.9) F(1.1,26.4) = 2.994, F(1.1,26.4) = 0.703,
n-3-PUFA group (n = 
13)‡
11.0 (2.2) 11.1 (2.0) 10.7 (2.5) p = 0.092 p = 0.555
CRC 1 § CRC 2 CRC 3
Resting energy expenditure (MJ/d):
Control group (n = 12) 6.74 (0.89) 6.41 (1.10) 6.41 (0.79) F(2,46) = 0.313, F(2,46) = 0.703,
n-3-PUFA group (n = 13) 6.53 (1.23) 6.59 (1.51) 6.57 (1.39) p = 0.733 p = 0.500
Resting energy expenditure (kJ/d/kg fat free body mass ||):
Control group (n = 12) 134 (15) - 132 (13) F(1,23) = 0.002, F(1,23) = 0.315,
n-3-PUFA group (n = 13) 133 (21) - 135 (14) p = 0.961 p = 0.580
Respiratory quotient:
Control group (n = 12) 0.86 (0.05) 0.87 (0.05) 0.86 (0.05) F(2,46) = 0.096, F(2,46) = 1.091,
n-3-PUFA group (n = 13) 0.85 (0.03) 0.84 (0.05) 0.85 (0.05) p = 0.908 p = 0.344
All data are means (SD). * MET-h, metabolic equivalent task-hours. † RM-ANOVA, repeated-measures analysis of variance. ‡ PUFA, 
polyunsaturated fatty acids. §CRC, Clinical Research Center. || Fat-free body mass data from dual-energy x-ray absorptiometry-scans were available 
only for CRC visits 1 and 3.Nutrition & Metabolism 2009, 6:24 http://www.nutritionandmetabolism.com/content/6/1/24
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ple size and short study duration, or due to differences
between the study diets other than n-3-PUFA.
Strengths of our study include the fact that all foods were
provided for a period of 16 weeks, and that the quality
and quantity of food consumed was assessed for each day
of the study. The n-3-PUFA and control diets were
designed to be identical except for the fatty acid composi-
tion. As all subjects were seen at least twice weekly by
study staff, and were encouraged to share with us any
deviation from the study protocol, we feel confident in
our assessment of their actual intake. Nevertheless, the
fact that subjects could have been non-compliant is a
potential limitation of this study.
We conclude that dietary n-3-PUFA do not have a signifi-
cant effect on plasma leptin and ghrelin concentrations,
appetite, ad libitum food intake, resting energy expendi-
ture, or body weight and fat mass in overweight or mod-
erately obese men and women.
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